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Abstract
Treatment of canine leishmaniasis (CanL) represents a challenge. Due to the high preva-
lence of renal disease associated to CanL, it is important to find an effective drug that does
not damage the kidneys. Marbofloxacin has been shown to be effective and well tolerated in
non-azotemic dogs with leishmaniasis. To evaluate the safety and efficacy of marbofloxacin
in dogs with leishmaniasis and decreased renal function, 28 dogs suffering from leishmania-
sis and chronic kidney disease (CKD) were treated with oral marbofloxacin at 2 mg/Kg/day
for 28 days. During treatment dogs were assessed by performing weekly physical exams,
measuring blood pressure and evaluating blood and urine parameters. Lymph node aspira-
tions were also obtained at days 0 and 28. The global clinical score decreased significantly,
from 6.2±3.4 to 4.7±3.1 (p = 0.0001), after treatment. Marbofloxacin also decreased para-
sitic load in 72% of the dogs. No significant differences in plasma creatinine, urine specific
gravity, urinary concentrations of cystatin C, ferritin and urinary protein loss were detected
during treatment. A transient but significant decrease in blood pressure was detected up to
day 14 (from 180.1±36.6 to 166.0±32.7 mmHg; p = 0.016). Moreover, dogs showed a signifi-
cant increase in plasma albumin concentration (from 15.0±5.2 to 16.6±3.9 g/L; p = 0.014)
and a significant decrease in globulin concentration (from 59.0±18.1 to 54.1±18.0 g/L; p =
0.005). The results demonstrate that, in addition to being effective for treatment of CanL,
marbofloxacin is a very safe drug in dogs with CKD and leishmaniasis.
Introduction
Canine leishmaniasis (CanL) is a parasitic disease caused by the protozoan Leishmania infan-
tum and transmitted by the bite of sandflies of the genus Phlebotomus. In the Mediterranean
countries, where infection rates are up to 63% [1], CanL represents one of the leading causes of
death in dogs [2]. CanL is an expanding disease and it has become one of the most important
canine diseases imported to Central Europe [3].
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The clinical presentation of CanL is variable and depends on the immune response of the
host, thus the infection in dogs can range from subclinical and self-limiting to severe disease
[4]. Three clinical presentations: cutaneous, mucocutaneous and visceral have been described
[5]. Affected dogs commonly develop kidney disease associated with glomerular immune com-
plex deposition [4, 6]. Kidney damage can progress to tubulointerstitial lesions and lead to
renal failure [4]. Renal disease can be diagnosed in approximately 50% of dogs with leishmani-
asis using laboratory tests [7]. Moreover, virtually 100% of dogs with leishmaniasis have histo-
pathologic lesions compatible with nephropathy [8].
Treatment of CanL is a challenge because of the intracellular localization of the parasite [9].
Drugs for treatment of CanL include meglumine antimoniate, aminosidine and miltefosine
[4], which are generally used in combination with allopurinol. Most of these treatments do not
achieve complete cure of the disease and some of them can cause important side effects [5, 10].
Vomiting, diarrhoea, lethargy and nephrotoxicity are common during treatments with penta-
valent antimonials and miltefosine [9–13]. Xanthine urolithiasis is a frequent complication
after prolonged administration of allopurinol [14]. The toxicity of these treatments may be
increased in dogs with decreased glomerular filtration rate [4]. In addition, dogs with renal
involvement usually have a slower response to the drugs that requires longer treatments and,
therefore, are more prone to develop adverse effects [15].
Considering the high prevalence of kidney disease in dogs with leishmaniasis, it would be
important to find an effective drug with reduced toxicity in patients with renal disease. Recent
data [16–18] suggest that marbofloxacin, a third generation fluoroquinolone, has similar effec-
tiveness than miltefosine or glucantime to treat CanL. In addition, it has been shown that mar-
bofloxacin does not induce changes in serum urea and creatinine in non-azotemic dogs and
also has little or no gastrointestinal side effects [18].
We hypothesized that marbofloxacin may be a safe and effective drug for treatment of dogs
with leishmaniasis and renal disease. To test this hypothesis, dogs with leishmaniasis and kid-
ney disease were treated with marbofloxacin and followed in a prospective open clinical trial.
Materials and methods
Dogs
Thirty dogs attended at the Veterinary Teaching Hospital of the University of Cordoba (Spain)
were studied. Sixteen dogs were males (53%) and 14 were females (47%). Dogs were aged 5.2
±2.8 (range 1–14) years and weighed 20.1±9.3 (range 6–50) Kg. Hounds were predominant
(16 dogs, 53%), followed by crossbreds (5 dogs, 17%), Boxers (5 dogs, 17%) and other compan-
ion dogs (Golden Retriever, Labrador Retriever, Pitbull, Argentinean Dogue) (4 dogs, 13%).
All the experimental procedures were approved by the Ethics Committee of the Veterinary
Teaching Hospital of the University of Cordoba. An informed consent was obtained from the
owner or person in charge of the dog prior to the inclusion in the study. To be accepted in the
study, dogs had to meet the following inclusion criteria:
1. Show at least one clinical sign of CanL (e.g. lymphadenomegaly, weight loss, dermatologic
signs) and be positive in a serologic test of CanL (Snap Leishmania Test, IDEXX Laborato-
ries, Barcelona, Spain).
2. Show evidence of chronic kidney disease (CKD), stage 1 to 4 according to the classification
criteria of the International Renal Interest Society (IRIS).
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3. Be free from other coinfections that may contribute to progression of kidney disease: Ehrli-
chia canis, Dirofilaria immitis, Anaplasma phagocytophilum, Anaplasma platys and Borrelia
burgdorferi (Snap 4Dx Test, IDEXX Laboratories, Barcelona, Spain).
4. Be free of urinary infection (negative urine culture).
5. Not have received any antibiotic, corticosteroid or anti-leishmanial treatment within the 60
days preceding inclusion.
Once admitted into the study, each dog underwent additional tests for the diagnosis of
leishmaniasis and for evaluation of renal disease. Diagnosis of CanL was confirmed by two
techniques: a) antibody evaluation by indirect immunofluorescence (IFI) performed on
serum; and, b) presence of Leishmania DNA by real time polymerase chain reaction (PCR) in
lymph node aspirates. The following parameters were evaluated for the diagnosis of kidney
disease: plasma creatinine (reference range in our laboratory, 0.5–1.4 mg/dL); plasma urea,
(reference range, 20 to 50 mg/dL); urine specific gravity (USG) (reference range>1030); urine
protein to creatinine ratio (UPC), (normal range <0.5); and blood pressure (reference range:
systolic blood pressure (SBP)<150 mmHg, diastolic blood pressure (DBP) <100 mmHg,
mean blood pressure (MBP) <125 mmHg). In addition to these parameters recommended by
IRIS to classify kidney disease, urinary concentrations of cystatin C and ferritin were mea-
sured. These parameters have recently been shown to be good markers of tubular (cystatin C)
and glomerular (ferritin) damage in dogs [19–21].
Treatment
All dogs received marbofloxacin (Marbocyl, Vetoquinol, Madrid, Spain) orally at a dose of 2
mg/Kg/day for 28 days. During the 28 days of treatment, there were isolated cases in which it
was necessary to prescribe other drugs to control signs related to renal disease: antiemetics
(n = 7), antacids (n = 7); and dermatologic signs: anti-seborrheic shampoos (n = 4). No drug
that may affect renal function or blood pressure was prescribed. There were no dietary changes
during the month of treatment.
Follow up
All dogs were monitored before and every week during the treatment on days: 0, 7, 14, 21 and
28. At each examination point, a physical exam was performed, blood pressure was measured
and blood and urine samples were obtained.
In the physical exam, dogs were assessed as previously reported [17] for: a) systemic signs
(lethargy, epistaxis and lymphadenopathy), b) dermatological signs (alopecia, hyperkeratosis,
seborrheic dermatitis, pyodermatitis, onychogryphosis, nodules and ulcers), c) musculo-skele-
tal signs (muscle atrophy, lameness and arthritis), d) gastro-intestinal signs (diarrhoea and
intestinal bleeding) and e) ocular signs (conjunctivitis, keratitis and uveitis). Each clinical sign
was scored according to its severity on a numerical scale from 0 to 3, as follows: 0, absent; 1,
mild; 2, moderate; and 3, severe; except for lymphadenomegaly, ulcers, nodules and arthritis
which were scored as 0, absent; 1, local; and 2, generalised. The sum of the clinical scores was
calculated by adding the points given to each of the 18 clinical parameters at each examination
time. In addition, body weight and rectal temperature were recorded at each examination.
Blood pressure was measured with an oscillometric blood pressure meter (petMAP graphic,
Ramsey Medical Inc. Florida, USA), which quantifies the SBP, DBP and MBP. The size (40%
of the limb perimeter) of the cuff was standardized for each dog. At all times, the cuff was
placed in the same limb and measurements were always recorded by the same operator. The
methodology was as follows: 5 measurements were obtained when the dog was quiet and
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relaxed in lateral recumbence. The higher and lower values were discarded and the mean of
the three remaining measurements was calculated for each dog at each time point.
Blood samples were obtained from the jugular vein at all examination times and placed in
heparin and EDTA-coated tubes. Samples were centrifuged and plasma was separated for mea-
surement of creatinine and urea. Urine was collected by cystocentesis to perform an urinalysis
that included: determination of USG by refractometry (Zuzi, Auxilab S.L., Navarra, Spain) and
quantitative determination of proteinuria by calculating the UPC.
On day 0 and day 28, additional testing was performed as follows:
1. A complete haematological and plasma biochemistry panel was obtained. Haematologic
parameters included: red and white blood cell count, leukocyte differential count, platelet
count, haemoglobin concentration, mean corpuscular haemoglobin concentration
(MCHC), mean corpuscular volume (MCV) and packed cell volume (PCV). The biochem-
istry panel included: alanine aminotransferase (ALT), alkaline phosphatase (ALP), albumin,
total proteins, albumin to globulins (A/G) ratio, total calcium (tCa), phosphorus (P), total
magnesium (tMg), sodium (Na), potasium (K), chloride (Cl), ionized calcium (iCa) and
venous blood gas analysis (pH, PCO2, bicarbonate, base excess and anion gap).
2. Urine concentrations of cystatin C and ferritin were measured.
3. Lymph node aspirates were obtained for measurement of parasitic load by quantitative
PCR. Lymph node aspirates were retrieved by fine-needle aspiration from the most
enlarged lymph node. The aspirates were washed with 500μL of sterile PBS and stored in
two aliquots of 250μL at -80˚C for DNA extraction.
Efficacy criteria
The treatment was considered effective if, between day 0 and day 28, the dog showed clinical
improvement (i.e. the sum of clinical scores was lower than before treatment), and the parasitic
load (lymph node quantitative PCR test findings) decreased. The treatment was classified as
inefficacious if the dog did not clinically improve, or deteriorated, and/or parasitic load did
not decrease.
Blood and urine measurements
Plasma (urea, creatinine, ALT, ALP, total proteins, albumin, P, tCa and tMg) and urine (creati-
nine, protein and ferritin) biochemical parameters were measured by spectrophotometry (Bio-
Systems S.A., Barcelona, Spain). Urine cystatin C was measured using an ELISA specifically
designed for its measurement in canine samples (BioVendor, Brno, Czech Republic). UPC was
calculated as follows:
UPC ¼ ð½protein in urine ðmg=dLÞÞ = ð½creatinine in urine ðmg=dLÞÞ
For creatinine measurements in urine the sample was diluted (1/50) in distilled water.
Blood cell counts were obtained by flow cytometry (LaserCyteDx, IDEXX Laboratories,
Barcelona, Spain). Electrolyte (Na, K, Cl, iCa) and acid-base parameters (pH, PCO2) were
measured with selective electrodes (Siemens RAPIDLab 860, Germany).
Polymerase chain reactions (PCR)
The DNA from lymph node aspirates was obtained using a DNA isolation kit (UltraClean
BloodSpin DNA, MoBIO Laboratories, CA, USA) [22]. The detection and quantification of
the DNA from Leishmania infantum was performed by real time PCR.
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Reactions were carried out in 96 wells PCR plates in a final volume of 20 μL (4 μL of DNA
+ 16 μL of Reaction Mix), containing 20 μM of each primer (Leish1: 5’-AACTTTTCTGGTC
CTCCGGGTAG-3’ and Leish2: 5’-ACCCCCAGTTTCCCGCC-3’(Stab Vida Laboratories,
Caparica, Portugal)), 10 μM of TaqMan Probe (FAM-5’-AAAAATGGGTGCAGAAAT-3’-non
fluorescent quencher-MGB (Applied Biosystems Laboratories, Foster City, CA, USA)) [23], and
the iTaq Universal Probes Supermix (Bio-Rad Laboratories, Hercules, CA, USA). The thermal
cycling profile used was one incubation step at 50˚C for 2 minutes and an initial denaturation
step at 95˚C for 10 minutes, followed by 40 cycles of denaturation at 95˚C for 15 seconds and
annealing-extension at 60˚C for one minute. Each amplification run contained positive and neg-
ative controls. All quantitative PCR analyses were performed in a Step One Plus Real Time PCR
System (Applied Biosystems Laboratories, Foster City, CA, USA). A standard curve was obtained
[24] using DNA extracted from six quantities of Leishmania infantum parasites (MCAN/ES/
1996/BCN150, zymodeme MON-1) ranging from 50,000 to 0.5 (dilution factor x10). The thresh-
old cycle (Ct) corresponding to the Y-intercept of each analysis (that is, the expected Ct value for
the estimated quantity of 1 parasite) was used as cut-off, being positive those samples whose Ct
values were Y-intercept value of each assay. The parasitic load in positive samples was extrapo-
lated from the intercept of each Ct value in the Y axis of the standard curve.
Statistical methods
Statistical analysis of the results was performed using a statistical software (SPSS version 15.0
for Microsoft Windows). A Kolmogorov—Smirnov test was carried out to test for normality.
All data sets, except ALT, AST, pH, urine cystatin C and parasitic load passed normality test-
ing. The effect of time on the normally distributed variables measured every week (urea, creati-
nine, UPC and blood pressure) was assessed by repeated measures of analysis of variance
using a general linear model. To compare the means of the normally distributed variables mea-
sured at day 0 and at day 28 paired sample Student’s t-test was used. Wilcoxon analysis was
used to compare means between day 0 to day 28 for non-normally distributed variables. Bon-
ferroni correction was conducted to counteract type I error when multiple tests were used to
evaluate a hypothesis. The Bonferroni adjusted p values for the different hypotheses related to
the effects of marbofloxacin were: for clinical improvement (p<0.01), for parasite load
(p<0.05), for renal function (p<0.008), for blood pressure (p<0.02), for haematology
(p<0.01), for protein profile (p<0.02), for liver enzymes (p<0.02), for electrolyte profile
(p<0.007) and for acid-base status (p<0.01).
The relationship between the main parameters was studied by Pearson correlation (p<0.01
was considered significant) and graphically displayed in a principal components analysis plot.
Values are given as the mean ± standard deviation (SD).
Results
One dog died in the course of the study and another one was lost for follow up because the
owners changed address. As a result, 28 of the 30 selected dogs completed the 28 days of treat-
ment with marbofloxacin. No important adverse events related to marbofloxacin treatment
were observed. Mild diarrhoea was reported in two dogs. Since diarrhoea resolved with no spe-
cific treatment, the follow-up of these dogs progressed in conformity with the study protocol.
Thus, the safety and efficacy of the treatment was evaluated in 28 dogs.
Clinical signs
Before initiating treatment (day 0), dermatological and systemic signs were predominant.
Onychogryphosis (71%, 20/28 dogs), seborrhoea (43%, 12/28 dogs) and hyperkeratosis (39%,
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11/28 dogs) were the most common skin lesions. Lymphadenomegaly, either local or general-
ized, was detected in most dogs (75%, 21/28 dogs). Lethargy (32%, 9/28 dogs) was also a com-
mon systemic sign. Gastro-intestinal (21%, 6/28 dogs), musculo-skeletal (11%, 3/28 dogs) and
ocular signs (4%, 1/28 dog) were less frequent. Epistaxis was found in 3/28 dogs (11%).
Clinical improvement was observed in 18/28 dogs (64%) after treatment (Table 1). The
global clinical score decreased significantly from 6.2±3.4 to 4.7±3.1 (p = 0.0001) after treatment
with marbofloxacin. Clinical improvement was more accentuated in dermatologic (46%, 13/28
dogs) and systemic signs (50%, 14/28 dogs). The score for dermatological signs decreased
from 3.8±3.2 to 3.0±2.8, p = 0.008, and the score for systemic signs decreased from 2.1±1.4 to
1.5±0.9, p = 0.01(Fig 1). No significant changes in body weight (20.1±9.3 vs 20.5±9.0 Kg) or
body temperature (38.7±0.6 vs 38.5±0.3˚C) were recorded after treatment.
Renal function
At day 0, mean CKD stage was 2.2±1.1, with 11 dogs in stage 1, 6 dogs in stage 2, 8 dogs in
stage 3, and 3 dogs in stage 4 (Table 2). Mean plasma concentrations of creatinine (2.3±1.5
mg/dL) and urea (104.5±81.2 mg/dL) were above reference ranges at day 0. Plasma creatinine
did not increase during treatment, in fact it showed a non-significant tendency to decrease
reaching values of 2.0±1.6 mg/dL at day 28. Plasma urea concentrations behaved similarly to
creatinine. Proteinuria, UPC0.5, was observed at day 0 in all dogs included in the study,
with mean UPC values of 3.8±2.4. Proteinuria was attenuated during treatment and a non-sig-
nificant decrease in UPC was already evident at day 7 and this tendency was maintained till
day 28 (Fig 2). No significant differences in either USG (1.022 ± 0.02 vs 1.021 ± 0.01), urinary
cystatin C concentration (7620 ± 11933 μg/g vs 7390 ± 11240 μg/g), or urinary ferritin (136.4
±87.8 vs 154.3±75.7 μg/g) were detected when comparing day 0 and day 28.
Blood pressure
Hypertension, as defined by IRIS (SBP >150 mmHg) was a clinical feature of the majority
(82.1%) of the dogs included in the study (Table 2). As shown in Fig 3, a transient but signifi-
cant decrease in blood pressure was detected up to day 14 (from 180.1±36.6 mmHg to 166.0
±32.7 mmHg, p = 0.016). When compared with day 0, a non-significant decrease in SBP (from
180.1±36.6 mmHg to 170.0±38.8 mmHg, p = 0.04).
Haematologic and biochemical parameters
The evolution of main haematological and biochemical parameters during treatment is sum-
marized in Table 3. The mild anaemia that was detected at day 0 was not affected by treatment.
Although initially dogs did not show leukocytosis (8.1±3.9 x 109/L), total leukocyte count
decreased significantly (p = 0.006) at the end of the treatment (6.1±2.7 109/L). Treatment with
marbofloxacin also resulted in attenuation of hypoalbuminemia (from 15.0±5.2 to 16.6±3.9 g/
L, p = 0.014) and hyperglobulinemia (from to 59.0±18.1 to 54.1±18.0 g/L, p = 0.005). No signif-
icant changes were observed in hepatic enzymes after treatment. Marbofloxacin treatment did
not influence the increased plasma phosphorus and decreased calcium levels found at day 0.
Similarly, other electrolytes (Na, K, Cl, tMg) that were within normal ranges at day 0 did not
change at day 28. Slight metabolic acidosis, that was not influenced by treatment with marbo-
floxacin, was also observed.
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Real-time PCR kinetic results
DNA isolation from lymph node aspirates was successful both pre- and post-treatment in 26
dogs. In two dogs DNA could not be obtained in both samples due to lack of sufficient tissue.
In one of the dogs in which DNA isolation was successful (dog n˚ 28 in Table 1) parasitic
DNA was not found in either pre- or post-treatment samples. This dog was maintained in the
study because it showed characteristic clinical signs and a high serum IFI titer (1/640). Thus,
changes in parasitic load were evaluated in 25 dogs. After treatment with marbofloxacin, the
mean parasitic load decreased from 16.0±23.2 parasites/μL on day 0 to 11.3±18.7 parasites/μL
on day 28, but the differences were not significant. When considered individually, parasitic
Table 1. Individual clinical score, antibody titers and parasitic load of the dogs under study before (at day 0) and after (at day 28) treatment with
marbofloxacin.
Dog Clinical score Antibody titers Parasitic load (parasites/μL)
Day 0 Day 28 Day 0 Day 0 Day 28
1 6 2 1/1280 19.4 1.4
2 4 4 1/320 80.5 5.7
3 1 2 1/320 - -
4 5 5 1/320 5.2 19.8
5 3 1 1/320 19.4 3.2
6 8 7 1/320 1.1 71.2
7 5 3 1/640 10.5 57.0
8* - - 1/640 - -
9 5 4 1/320 0.2 0.1
10 11 8 1/640 0.2 0.1
11 7 5 1/640 0.1 0.01
12 5 3 1/640 6.0 4.0
13 9 5 1/1280 9.1 0.6
14 12 11 1/640 0.3 1.6
15 4 3 1/1280 9.7 9.3
16 3 1 1/200 3.3 1.5
17 3 4 1/400 8.0 2.2
18 5 5 1/640 16.6 11.8
19 14 9 1/320 0.1 0.03
20 9 7 1/640 14.7 2.4
21 9 9 1/1280 10.7 4.4
22 6 2 1/640 49.3 42.9
23 5 5 1/320 34.3 0.03
24 3 2 1/640 - -
25 12 13 1/320 11.3 24.2
26* - - 1/160 - -
27 2 2 1/320 0.5 12.4
28 6 2 1/640 - -
29 10 5 1/640 85.3 1.1
30 2 2 1/1280 4.2 7.5
*: dog that did not complete the study. The results obtained from these two dogs were not included in any statistical analysis. Antibody titers: normal values
are considered from absence of title to 1/40; values greater than 1/160 are considered seropositive.
There are no statistical correlations between the parameters shown: at day 0: clinical score and antibody titers: r = 0.030, p = 0.884; clinical score and
parasitic load: r = -0.090, p = 0.667; at day 28: clinical score and antibody titers: r = -0.076, p = 0.708; clinical score and parasitic load: r = -0.190, p = 0.364.
https://doi.org/10.1371/journal.pone.0185981.t001
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load decreased in 18/25 dogs (72%) (Table 1). The reduction in parasitic load in these 18 dogs
from 20.4±26.0 parasites/μL to 5.0±10.0 parasites/μL, was statistically significant (p = 0.018).
All dogs in which parasitic load decreased also showed clinical improvement, in fact, the
improvement in clinical score was more accentuated in dogs that decreased parasitic load
(from 6.6±3.1 to 4.7±2.4, p = 0.01) than in dogs that did not (in which the clinical score was
reduced from 7.1±3.8 to 6.1±4.2, p = 0.111). Therefore, according to the efficacy criteria previ-
ously set, the treatment was efficacious in 18 dogs (72% of the population).
Correlations
At day 0 the following significant correlations were found: Parasitic load was correlated with
UPC (r = -0.516, p = 0.008) and with globulins (r = 0.559, p = 0.004). Albumin was correlated
with UPC (r = -0.623, p<0.001) and with DBP (r = -0.485, p = 0.009). The UPC was correlated
with DBP (r = 0.572, p = 0.001) and with MBP (r = 0.533, p = 0.003). Antibody titers correlated
with renal parameters: urea (r = 0.681, p<0.001) and creatinine (r = 0.648, p<0.001). Urine
cystatin C had very good correlation with traditional markers of renal function: urea
(r = 0.662, p<0.001), creatinine (r = 0.696, p<0.001) and phosphate (r = 0.619, p<0.001).
At day 28 the following significant correlations were found: Parasitic load was correlated
with packed cell volume (r = -0.548, p = 0.005) and with DBP (r = 0.548, p = 0.005). Albumin
was well correlated with urine ferritin (r = -0.629, p<0.001) and with DBP (r = -0.468,
p = 0.01). The UPC maintained correlation with albumin, but weaker (r = -0.402, p = 0.03)
than at time 0, and with total proteins (r = 0.590, p = 0.001). Antibody titers correlated very
well with renal parameters: urea (r = 0.638, p<0.001), creatinine (r = 0.609, p = 0.001) and
cystatin C (r = 0.559, p = 0.002). Urine cystatin C, as in day 0, had very good correlations with
traditional renal parameters: urea (r = 0.725, p<0.001), creatinine (r = 0.846, p<0.001) and
phosphate (r = 0.765, p<0.001). However, urine ferritin was not correlated with renal parame-
ters, but showed a good correlation with total proteins (r = -0.513, p = 0.005), albumin (r =
Fig 1. Clinical scores before (at day 0) and after (at day 28) treatment with marbofloxacin in the dogs
under study. Values are expressed as the mean±standard deviation. ap<0.01 vs day 0.
https://doi.org/10.1371/journal.pone.0185981.g001
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-0.629, p<0.001) and DBP (r = 0.480, p = 0.01). A strong correlation between Anion Gap and
SBP (r = 0.696, p = 0.003) was also found.
The interrelation between the main variables studied is graphically shown in a principal
components analysis plot (Fig 4).
Discussion
This study was aimed at investigating the safety and efficacy of treatment with marbofloxacin
in dogs affected by leishmaniasis that had decreased renal function. The results show that mar-
bofloxacin is a safe and effective drug that does not aggravate renal disease in dogs with
leishmaniasis.
Table 2. Individual renal function biomarkers of the dogs under study before (at day 0) and after (at day 28) treatment with marbofloxacin.








Day 0 Day 0 Day 28 Day 0 Day 28 Day 0 Day 28 Day 0 Day 28 Day 0 Day 28 Day 0 Day 28
1 3 3.4 4.1 227.8 253.3 5.3 7.8 175 158 17830.7 38371.7 109.9 110.7
2 1 1.0 0.9 47.1 55.4 0.8 2.5 107 122 54.4 335.9 379.3 198.1
3 1 0.8 0.6 20.3 19.0 0.6 0.02 102 107 29.3 10.7 51.3 28.6
4 1 1.2 0.7 19.7 24.6 2.9 2.0 164 152 120.6 55.6 59.1 110.4
5 1 1.0 0.8 36.2 41.4 3.3 1.9 121 91 66.0 132.4 49.5 84.2
6 1 1.4 1.4 47.9 99.4 2.7 2.1 137 148 1333.4 3027.5 170.0 297.5
7 2 2.0 2.7 152.5 116.2 8.0 2.4 161 192 33998.6 25461.5 215.2 191.7
8* 4 6.6 - 359.2 - 3.0 - 126 - - - - -
9 1 1.4 0.9 61.7 36.2 6.3 3.9 177 111 45.4 53.1 207.1 268.5
10 1 1.2 0.9 49.8 43.3 0.6 0.1 117 104 711.4 23.7 92.6 53.6
11 3 3.0 3.7 241.2 250.3 6.2 3.6 172 160 4767.2 9006.3 75.4 101.9
12 2 1.9 2.0 99.8 133.1 4.1 2.6 159 155 3657.5 11810.0 113.6 125.6
13 4 5.4 4.7 301.4 365.1 4.4 2.1 186 175 21055.0 21829.2 57.9 74.3
14 2 1.8 1.1 117.7 89.2 9.3 6.1 183 173 2644.6 1624.0 164.7 221.7
15 3 2.9 4.4 136.1 182.0 5.1 3.3 178 171 1000.8 23964.7 135.5 135.7
16 3 4.9 1.5 126.8 51.55 5.8 3.4 207 209 23007.9 2560.4 139.6 196.7
17 2 1.8 0.7 79.0 39.0 5.9 5.4 209 169 18395.9 1203.9 146.5 282.0
18 1 1.0 0.6 19.4 36.4 2.8 0.2 204 180 33.4 59.7 101.0 162.4
19 1 0.9 0.7 54.2 42.9 2.7 4.9 211 230 361.0 214.8 125.4 245.7
20 3 2.5 1.6 106.4 105.9 5.2 2.9 211 231 1723.8 318.4 254.2 224.0
21 3 3.7 3.2 192.6 126.1 1.7 2.1 185 219 565.4 336.7 74.5 124.6
22 4 5.5 7.5 270.3 163.1 1.0 0.6 196 219 40058.8 34213.9 130.9 117.0
23 2 1.5 1.1 16.7 28.5 2.0 3.4 202 144 83.9 1063.9 35.2 101.4
24 3 2.3 1.7 63.8 81.5 2.5 2.1 177 161 92.1 680.5 143.8 139.3
25 2 2.0 1.6 89.2 86.6 4.4 1.7 237 193 8897.2 4841.0 82.4 211.6
26* 2 1.6 - 106.5 - 2.9 - 250 - - - - -
27 1 1.0 1.6 28.8 89.7 3.6 4.0 221 212 44.3 141.8 389.7 251.7
28 4 5.1 2.6 155.1 142.3 3.7 6.9 233 176 30808.3 14493.2 143.7 87.6
29 1 1.0 0.7 24.0 28.0 0.5 0.1 195 194 42.9 34.4 82.0 35.7
30 3 3.2 3.0 139.6 118.9 3.8 5.4 217 204 1965.8 11104.9 88.5 140.6
*: dog that did not complete the study. The results obtained from these two dogs were not included in any statistical analysis.
CKD: chronic kidney disease; SBP: systolic blood pressure; UPC: urine protein to creatinine ratio.
https://doi.org/10.1371/journal.pone.0185981.t002
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Fig 2. Concentrations of plasma creatinine (A), plasma urea (B) and urine protein to creatinine (UPC)
ratio (C) on days 0, 7, 14, 21 and 28 of treatment with marbofloxacin in the dogs under study. Values
are expressed as the mean±standard deviation.
https://doi.org/10.1371/journal.pone.0185981.g002
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The efficacy of marbofloxacin for treatment of leishmaniasis has been previously evaluated
in dogs with intact renal function. Rougier et al. (2012) [18] showed a clinical improvement
comparable with what we have found after 28 days of treatment. It is important to note that,
theoretically, the response to treatment should not be as good in dogs with renal disease since
they usually show progressive signs related to organ damage (e.g. gastrointestinal signs) which
do not necessarily improve after eliminating the parasite [15]. The response to treatment was
not correlated with the CKD stage, suggesting that marbofloxacin is likely to be effective even
in dogs with severe renal disease, which is the subpopulation of dogs with leishmaniasis in
which other treatments may be contraindicated. In addition to the anti-leishmanial actions,
the antibiotic effect of marbofloxacin could have contributed to improvement of clinical signs
in which secondary bacterial infections may play a role (e.g. dermatologic signs). In our study
we only evaluated the dogs during and at the end of the treatment with marbofloxacin because,
for ethical reasons, after day 28 all dogs started another treatments (allopurinol and different
drugs for CKD); thus, from this time on it was not possible to isolate the effect of marbofloxa-
cin. However, as shown by Rougier et al. (2012) [18], clinical signs keep improving for several
months after finishing treatment with marbofloxacin.
The efficacy of the treatment was assessed by both clinical improvement and decrease in
parasitic load. The PCR results showed a decrease in parasitic load in most dogs but the drug
was not able to completely eliminate the parasite from lymph nodes. In addition, there was a
subpopulation of dogs in which parasitic load did not decrease. It is interesting to note that the
improvement in clinical score was more accentuated in dogs that decreased parasitic load than
in dogs that did not. Evidence for a relationship between parasitic load and clinical manifesta-
tions has been previously reported in dogs with leishmaniasis [25]. However, a lack of correla-
tion between changes in clinical signs and parasitic load has also been reported [26–28], and it
is known that anti-leishmanial treatments do not eliminate all parasites [27, 29–35]. Serologi-
cal CanL titers were not repeated after treatment because, although they have been recently
reported as potentially useful shortly after treatment [36], data in the literature support that a
minimum period of 6 months is required to find significant changes in IFI results [5]. Thus
Fig 3. Blood pressure measurement on days 0, 7, 14, 21 and 28 of treatment with marbofloxacin in the
dogs under study. Values are expressed as the mean±standard deviation. ap<0.02 vs day 0, bp<0.02 vs day
7.
https://doi.org/10.1371/journal.pone.0185981.g003
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most authors consider that serology cannot be used as a reliable criterion in the short-time fol-
low-up of the clinical evolution of treated dogs [5, 33].
Renal disease secondary to immune complex deposition is very common in dogs with leish-
maniasis. Renal damage usually starts at the glomerulus and then progress to affect the entire
nephron. The clinical pathology profile in the dogs of this study (proteinuria, azotemia,
increased urine ferritin) points to a predominance of glomerular dysfunction, although some
tubular dysfunction was also present as evidenced by the increase in urinary cystatin C. The
prevalence of renal damage in CanL is very high and it is estimated that about 50% of dogs
with leishmaniasis show changes in clinical pathology characteristic of renal disease. Since
most effective therapies for treatment of CanL are known to induce renal injury, there is a
need for effective treatments that preserve renal function. Marbofloxacin has been shown to be
safe in dogs with normal renal function. The main objective of this study was to evaluate with
detail the renal changes induced by treatment with marbofloxacin in a population of dogs with
Table 3. Haematological and biochemical parameters of 28 dogs with leishmaniasis and CKD before (at day 0) and after treatment (at day 28).
Time
Parameters Day 0 Day 28
Haematology
Erythrocytes (1011/L) 5.0 ± 1.5 4.8 ± 1.4
Packed cell volume (%) 35.4 ± 10.0 33.6 ± 9.4
Haemoglobin (mg/dL) 11.5 ± 3.4 10.8 ± 3.0
Leukocytes (109/L) 8.1 ± 3.9 6.1 ± 2.7a
Platelets count (1011/L) 189.2 ± 93.3 187.8 ± 85.1
Protein profile
Total protein (g/L) 74.3 ± 20.3 70.7 ± 19.5b
Albumin (g/L) 15.0 ± 5.2 16.6 ± 3.9b
Globulins (g/L) 59.0 ± 18.1 54.1 ± 18.0b
Liver enzymes
Alanine aminotransferase (IU/L) 43.5 ± 26.3 39.6 ± 31.4
Aspartate aminotransferase (IU/L) 54.0 ± 27.6 52.9 ± 29.6
Alkaline phosphatase (IU/L) 46.8 ± 30.6 41.8 ± 30.4
Electrolytes
Sodium (mmol/L) 147.0 ± 6.4 144.6 ± 4.8
Potassium (mmol/L) 4.4 ± 0.5 4.6 ± 0.7
Ionized calcium (mmol/L) 1.13 ± 0.09 1.14 ± 0.09
Chloride (mmol/L) 120.6 ± 6.5 120.0 ± 6.9
Phosphate (mg/dL) 7.0 ± 3.1 7.0 ± 3.2
Total calcium (mg/dL) 8.3 ± 1.4 8.0 ± 1.6
Total magnesium (mg/dL) 2.3 ± 0.8 2.2 ± 0.6
Acid-Base
pH 7.41 ± 0.07 7.42 ± 0.07
Bicarbonate (mmol/L) 20.1 ± 4.0 20.0 ± 2.6
PCO2 (mmHg) 32.8 ± 5.9 31.9 ± 6.4
Base Excess (mmol/L) -3.6 ± 4.2 -3.2 ± 2.7
Anion Gap (mmol/L) 9.1 ± 9.1 9.8 ± 10.6
Values are expressed as the mean±standard deviation.
a p<0.01 vs day 0.
b p<0.02 vs day 0.
https://doi.org/10.1371/journal.pone.0185981.t003
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Fig 4. Principal components analysis plot. Interrelation between the main parameters studied at day 0
(A) and at day 28 (B). Alb: albumin; AbTiter: antibody titer; Crea: creatinine; CScore: clinical score; DBP:
diastolic blood pressure; Glob: globulins; P: phosphate; ParLoad: parasitic load; PCV: packed cell volume;
SBP: systolic blood pressure; UCystatin: urine cystatin C; UFerritin: urine ferritin; UPC: urine protein to
creatinine ratio.
https://doi.org/10.1371/journal.pone.0185981.g004
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CKD stages 1–4. Marbofloxacin treatment did not induce further renal damage in the dogs of
this study since renal parameters did not show impairment after administering marbofloxacin
for 28 days.
A non-significant decrease in the urinary loss of proteins, which was more accentuated in
dogs with higher baseline values of UPC, was detected in the course of the treatment. A reduc-
tion in proteinuria in dogs with leishmaniasis has been previously reported after treatment
with glucantime [37] and with allopurinol [14]. The time frame for the decrease in protein loss
by urine is similar after treatment with marbofloxacin and glucantime and much shorter than
after treatment with allopurinol. The reduction in systemic blood pressure observed after treat-
ment may also have contributed to the decrease in protein loss by urine. In our study a strong
correlation was found between blood pressure and UPC. These data are in agreement with
previous reports linking hypertension with proteinuria in dogs with leishmaniasis [7, 38–40].
Systemic hypertension is a common finding in dogs with renal disease secondary to leish-
maniasis [7]. In humans, hypertension may appear early in the course of renal disease and has
been reported not to be directly correlated with plasma creatinine concentrations [41]. In our
study, there was a weak correlation between plasma creatinine and SBP at the beginning (day
0) but not at the end (day 28) of the study. The lack of correlation at the end of the study may
reflect the fact that treatment resulted in more effective decrease in blood pressure than in
plasma creatinine. In any case, the decline in blood pressure observed after treatment with
marbofloxacin is an indication of renal improvement. The decrease in blood pressure found in
the present study would reduce the risk of organ damage from very high to moderate (IRIS
staging for CKD).
The lack of deleterious effect of marbofloxacin on renal function is supported by the fact
that plasma concentrations of creatinine and urea did not increase during treatment. The ten-
dency to reduced azotemia detected in the study could be related to the general improvement
after treatment which would result in better hydration of the dogs. Plasma urea and creatinine
correlated with antibody titers but not with PCR results at day 0, suggesting that renal damage
is more linked to the host immune response than to the actual parasitic load.
An increase in plasma proteins secondary to hyperglobulinemia and a decrease in plasma
albumin, that result in a reduced A/G ratio, are common findings in dogs with leishmaniasis.
Parasitic load showed significant correlation with plasma globulins. After treatment with mar-
bofloxacin a significant increase in the A/G ratio was observed. The increase in the A/G ratio
was due to both a decrease in globulins, secondary to decreased parasitic stimulation of the
immune system, and to an increase in albumin. In dogs with leishmaniasis hypoalbuminemia
is due to renal loss, decreased synthesis secondary to chronic inflammation and decreased pro-
tein intake [34]. In agreement with Pierantozzi et al. (2013) [37], at day 0 a significant inverse
correlation was found between UPC and plasma albumin, suggesting that renal loss was a
major factor determining hypoalbuminemia. As previously reported [18, 42] plasma albumin
concentration increased after treatment. Thus, the accumulated reduction in UPC may have
played an important role in the increase in albumin after treatment.
The toxicity of drugs used for the treatment of CanL is well known and this is one of the
major limitations when using these treatments in dogs with reduced renal function. Both
meglumine antimoniate and miltefosine have been reported to cause gastrointestinal side
effects (vomiting, diarrhoea, anorexia) [9, 10, 12, 13]. In addition, antimonials are highly neph-
rotoxic and dogs treated with glucantime have been reported to suffer severe tubular damage
(tubular cell apoptosis and necrosis) [11]. Renal toxicity has also been reported after treatment
with miltefosine in humans [43, 44]. Treatment with marbofloxacin was very well tolerated
and only two dogs showed minor self-limiting episodes of diarrhoea. In addition to the lack of
deleterious actions on the kidneys, and in contrast to antimonials [34], marbofloxacin did not
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increase plasma concentrations of liver enzymes. Moreover, no significant changes were
detected after treatment in any of the multiple biochemical parameters under study.
In conclusion, the results of this study demonstrate that, in addition to be effective for treat-
ment of CanL, marbofloxacin is a very safe drug in dogs with CKD and leishmaniasis.
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mens of marbofloxacin in canine visceral leishmaniosis: a pilot study. Vet Parasitol. 2008; 153:244–
254. https://doi.org/10.1016/j.vetpar.2008.01.041 PMID: 18337012
18. Rougier S, Hasseine L, Delaunay P, Michel G, Marty P. One-year clinical and parasitological follow-up
of dogs treated with marbofloxacin for canine leishmaniosis. Vet Parasitol. 2012; 186:245–253. https://
doi.org/10.1016/j.vetpar.2011.11.016 PMID: 22130335
19. Monti P, Benchekroun G, Berlato D, Archer J. Initial evaluation of canine urinary cystatin C as a marker
of renal tubular function. J Small Anim Pract. 2012; 53:254–259. https://doi.org/10.1111/j.1748-5827.
2012.01198.x PMID: 22489749
20. Sasaki A, Sasaki Y, Iwama R, Shimamura S, Yabe K, Takasuma K, et al. Comparison of renal biomark-
ers with glomerular filtration rate in susceptibility to the detection of gentamicin-induced acute kidney
injury in dogs. J Comp Pathol. 2014; 151:264–270. https://doi.org/10.1016/j.jcpa.2014.06.001 PMID:
25086870
21. Garcı́a-Martı́nez JD, Martinez-Subiela S, Tvarijonaviciute A, Caldin M, Ceron JJ. Urinary ferritin and
cystatin C concentrations at different stages of kidney disease in leishmaniotic dogs. Res Vet Sci. 2015;
99:204–207. https://doi.org/10.1016/j.rvsc.2015.01.002 PMID: 25639693
22. Carcelén J, Iniesta V, Fernández-Cotrina J, Serrano F, Parejo JC, Corraliza I, et al. The chimerical
multi-component Q protein from Leishmania in the absence of adjuvant protects dogs against an experi-
mental Leishmania infantum infection. Vaccine. 2009; 27:5964–5973. https://doi.org/10.1016/j.vaccine.
2009.07.069 PMID: 19666153
23. Francino O, Altet L, Sánchez-Robert E, Rodriguez A, Solano-Gallego L, Alberola J, et al. Advantages of
real-time PCR assay for diagnosis and monitoring of canine leishmaniosis. Vet Parasitol. 2006;
137:214–221. https://doi.org/10.1016/j.vetpar.2006.01.011 PMID: 16473467
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